First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Background The phase III, randomized, open-label ENSURE study (NCT01342965) evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China, Malaysia and the Philippines with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC). Pati...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
Oxford University Press on behalf of the European Society for Medical Oncology
2015
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/44211/ http://irep.iium.edu.my/44211/ http://irep.iium.edu.my/44211/ http://irep.iium.edu.my/44211/2/firstline_erlotinib.pdf http://irep.iium.edu.my/44211/6/44211_First-line%20erlotinib%20versus%20gemcitabine_SCOPUS.pdf |